149 related articles for article (PubMed ID: 10732772)
1. Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer.
Kumar A; Collins HM; Scholefield JH; Watson SA
Br J Cancer; 2000 Feb; 82(4):960-5. PubMed ID: 10732772
[TBL] [Abstract][Full Text] [Related]
2. Preoperative radiotherapy and extracellular matrix remodeling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components.
Angenete E; Oresland T; Falk P; Breimer M; Hultborn R; Ivarsson ML
Acta Oncol; 2009; 48(8):1144-51. PubMed ID: 19863222
[TBL] [Abstract][Full Text] [Related]
3. Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion.
Speake WJ; Dean RA; Kumar A; Morris TM; Scholefield JH; Watson SA
Eur J Surg Oncol; 2005 Oct; 31(8):869-74. PubMed ID: 16081236
[TBL] [Abstract][Full Text] [Related]
4. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
5. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
6. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
7. Preoperative radiotherapy in rectal cancer: treatment results of three different dose regimens.
Klenova A; Parvanova V; Georgiev R; Gesheva N
J BUON; 2006; 11(2):161-6. PubMed ID: 17318965
[TBL] [Abstract][Full Text] [Related]
8. Decreased type IV collagenase activity in experimental pancreatic fibrosis.
Ng EK; Barent BL; Smith GS; Joehl RJ; Murayama KM
J Surg Res; 2001 Mar; 96(1):6-9. PubMed ID: 11180989
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression.
Eagleton MJ; Peterson DA; Sullivan VV; Roelofs KJ; Ford JA; Stanley JC; Upchurch GR
J Surg Res; 2002 May; 104(1):15-21. PubMed ID: 11971672
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy.
Unsal Kilic D; Uner A; Akyurek N; Erpolat P; Dursun A; Pak Y
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):196-203. PubMed ID: 17071013
[TBL] [Abstract][Full Text] [Related]
12. Effects of two conventional preoperative radiation schedules on anastomotic healing in the rat colon.
Bedirli A; Kerem M; Karahacioglu E; Ofluoglu E; Yilmaz TU; Pasaoglu H; Tater OP; Sakrak O; Pak Y
Eur Surg Res; 2007; 39(3):141-7. PubMed ID: 17337891
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic activity during cortical development is distinct from that involved in hypoxic ischemic injury.
Ranasinghe HS; Williams CE; Christophidis LJ; Mitchell MD; Fraser M; Scheepens A
Neuroscience; 2009 Jan; 158(2):732-44. PubMed ID: 18809469
[TBL] [Abstract][Full Text] [Related]
14. Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas.
Inaki N; Tsunezuka Y; Kawakami K; Sato H; Takino T; Oda M; Watanabe G
J Heart Lung Transplant; 2004 Feb; 23(2):218-27. PubMed ID: 14761770
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
17. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
18. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
19. Short versus conventional preoperative radiotherapy of rectal cancer: indications.
Klenova A; Georgiev R; Kurtev P; Kurteva G
J BUON; 2007; 12(2):227-32. PubMed ID: 17600877
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
